GlaxoSmithKline: Fasenra approved for maintenance treatment of severe eosinophilic asthma in adults and adolescents aged 12 years and older.

On March 31st, Sina Finance reported that GlaxoSmithKline recently announced that the China National Medical Products Administration has approved Nucala for maintenance treatment of severe eosinophilic asthma in adults and adolescents aged 12 and above. The approval of Nucala for the treatment of severe asthma is based on data from the phase III clinical trials SWIFT-1 and SWIFT-2. In these studies, in comparison to the placebo group, dosing with mepolizumab twice a year in addition to standard treatment, resulted in a continuous reduction in asthma exacerbations.